Swiss clinical-stage radiopharmaceutical company Nuclidium completed a Series B financing round, raising CHF 79 million (EUR 84 million). Vischer advised Nuclidium throughout the operation, while Walder Wyss advised Angelini Ventures, Kurma Partners and Wellington Partners, in connection